米托蒽醌毫微球在裸小鼠人肝癌模型体内的靶向性研究

米托蒽醌毫微球在裸小鼠人肝癌模型体内的靶向性研究

张志荣, 廖工铁, 侯世祥

华西医科大学药学院, 成都 610044

收稿日期:1994-12-08 修回日期:1995-06-05 出版日期:1995-12-15 发布日期:1995-12-15

Targeting Effect Studyof 3H-Mitoxantrone Nanosphereson Hepatocellular Carcinoma (HCC) Modelin Nude Mice

Zhi-Rong Zhang, Gong-Tie Liao, Shi-Xiang Hou

School of Pharmacy, West China University of Medical Sciences, Chengdu 610044

Received:1994-12-08 Revised:1995-06-05 Online:1995-12-15 Published:1995-12-15

摘要/Abstract

摘要： 采用液体闪烁计数技术研究厂氖标记米托惠醌聚氰基丙烯酸正丁酯毫微球(3H-DHAQ-PBCA-NS)在常位及异位(腋下)裸小鼠人肝癌模型体内各脏器、肌肉、肝常位肿瘤组织和腋下肿瘤组织中的分布。证明该制剂具有良好的肝靶向作用, 肝脏中的含量为体内总药量的71.31±10.49%(n = 5)。并发现其在常位肿瘤组织中的含量高于肝组织中的含量, 腋下肿瘤组织中的含量高于腋下肌肉组织中的含量, 但均无显著性差异。为该制剂的进一步研究提供了一定的科学依据。

关键词: 米托蒽醌毫微球, 肝癌, 裸小鼠人肝癌模型, 靶向制剂, 靶向性

Abstract: The distribution of 3H-mitoxantrone polybutyl cyanoacrylate nanospheres 3H-DHAQ-PBCA-NS)in the viscera, muscle and tumors of human hepatocellular carcinoma (HCC)model in nude mice was studied with liquid scintillation counting techniique. The results showed that the 3H-DHAQ-PBCA-NS had remarkable liver targeting effect. The content of 3H-DHAQ-PBCA-NSin liver and heterotopic liver tumor was found to be 71.31±10.49% of total amount of drug in animal body. It was also found that the content of 3H-DHAQ-PBCA-NS in liver was higher than that in liver tissue, and the content of 3H-DHAQ-PBCA-NS in annpit tumor was higher than that in armpit muscle tissue, but had no significant difference; It provides an ideal preparation for the DHAQ admini-stration.

Key words: Mitoxantrone nanospheres, Liver cancer, Human hepatocellular carcinoma model in nude mice, Targeted drug delivery system

Supporting:

张志荣, 廖工铁, 侯世祥. 米托蒽醌毫微球在裸小鼠人肝癌模型体内的靶向性研究[J]. .

Zhi-Rong Zhang, Gong-Tie Liao, Shi-Xiang Hou. Targeting Effect Studyof 3H-Mitoxantrone Nanosphereson Hepatocellular Carcinoma (HCC) Modelin Nude Mice[J]. .

[1]	石阿茜, 沈阗阗, 夏文彬, 席莉莉, 王利军, 魏玉辉. 淫羊藿素通过线粒体通路增强索拉非尼的诱导凋亡作用[J]. 中国药学(英文版), 2022, 31(12): 928-937.
[2]	董志勇, 邱仙土, Stacy A. Kujawa, S.M. Shariful Islam, 张杰. 华蟾素注射液治疗中晚期原发性肝癌的统评价和Meta分析[J]. 中国药学(英文版), 2019, 28(4): 264-275.
[3]	石继凤, 居瑞军, 孙梦舸, 李秀英, 赵曜, 曾凡, 吕万良. 培美曲塞-磷脂偶联物修饰的靶向性舒尼替尼与长春瑞滨脂质体的研制及其在体外对耐药性乳腺癌的抑制效应[J]. 中国药学(英文版), 2014, 23(5): 287-294.
[4]	李井泉, 仰浈臻, 孟婷婷, 齐宪荣. 肝癌靶向的阳离子脂质体共递送多西他赛和siRNA的研究[J]. 中国药学(英文版), 2014, 23(10): 667-673.
[5]	贾琳, 徐波, 郭维, 葛泽梅, 李润涛, 崔景荣^*. TM208与5-氟尿嘧啶联合应用对小鼠肝癌H22移植瘤的抗肿瘤作用及其机制研究[J]. , 2011, 20(6): 615-626.
[6]	郑愉, 孟祥豹, 李树春, 黄河清, 李中军^, 李庆^. 5-半乳糖基修饰环磷酰胺衍生物的合成及其抗肿瘤活性研究 [J]. , 2010, 19(5): 327-340.
[7]	张志荣, 永井恒司. 靶向给药系统的多室线性循环药物动力学模型研究[J]. , 1996, 5(2): 81-87.
[8]	李萍, 王佾先, 徐国钧, 徐珞珊. 蒲圻贝母中蒲贝酮碱的抗肿瘤活性[J]. , 1995, 4(4): 217-220.
[9]	魏树礼, 孙贻春, 张敬石, 谭惟薇, 谢敬霞, 李选, 朱建纲. 丝裂霉素葡聚糖微球的研究 [J]. , 1992, 1(1): 33-40.